Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMohammad AlhousaniEME MariottiPFPriyansh Faldu

Discussion

Loading...

Member takes

Overview

Retrospective study shows improved survival in chronic myelomonocytic leukemia patients receiving transplant, indicating benefits across risk categories.

Key Points

  • The study examines the survival impact of allogeneic stem cell transplant in chronic myelomonocytic leukemia patients at Mayo Clinic.
  • Retrospective analysis of 775 patients with chronic myelomonocytic leukemia
  • Patients categorized by BLAST and BLAST-Mol risk models
  • Overall survival compared between transplant and non-transplant groups
  • Overall survival was longer in the transplant cohort (median 77 months) compared to non-transplant (median 28 months)
  • Significant survival benefits were evident across all risk groups after adjusting for baseline risk
  • Patients with lower bone marrow blast percentages had the best outcomes post-transplant.

Cite This Study

Alhousani et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df78https://doi.org/10.1182/blood-2025-5636
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CMML2AML: Machine-learning discovery of co-mutations predictive of blast transformation in chronic myelomonocytic leukemia2025
  2. 2Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center2025
  3. 3Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation2025
  4. 4Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification2025
  5. 5Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study2025